| 000 | 01468 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516165028.0 | ||
| 264 | 0 | _c20150625 | |
| 008 | 201506s 0 0 eng d | ||
| 022 | _a1520-5762 | ||
| 024 | 7 |
_a10.3109/03639045.2013.829487 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhao, Yanli | |
| 245 | 0 | 0 |
_aPluronic-poly (acrylic acid)-cysteine/Pluronic L121 mixed micelles improve the oral bioavailability of paclitaxel. _h[electronic resource] |
| 260 |
_bDrug development and industrial pharmacy _cNov 2014 |
||
| 300 |
_a1483-93 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcrylic Resins _xchemistry |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aCysteine _xchemistry |
| 650 | 0 | 4 | _aDrug Carriers |
| 650 | 0 | 4 | _aIntestinal Absorption |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicelles |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aParticle Size |
| 650 | 0 | 4 |
_aPoloxamer _xchemistry |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aVerapamil _xpharmacology |
| 700 | 1 | _aLi, Yanli | |
| 700 | 1 | _aGe, Jianjun | |
| 700 | 1 | _aLi, Na | |
| 700 | 1 | _aLi, Ling-Bing | |
| 773 | 0 |
_tDrug development and industrial pharmacy _gvol. 40 _gno. 11 _gp. 1483-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/03639045.2013.829487 _zAvailable from publisher's website |
| 999 |
_c23028799 _d23028799 |
||